Bayer (XTRA:BAYN) has put a fresh spotlight on its pharmaceuticals arm after committing US$2.2b to a new manufacturing hub in New Albany, Ohio, in line with its focus on specialty treatments.
Against that backdrop, Bayer’s 1-day share price return of 1.09% to €44.44 comes after the stock fell 9.03% over 30 days and 10.48% over 90 days. A 60.43% 1-year total shareholder return signals momentum that has built over a longer horizon as investors weigh fresh pharma investments, new product launches and recent financing moves.
Capitalize on the renewed focus on specialty pharma by Bayer and scan a curated set of 178 high quality undervalued stocks with resilient cash flows and balance sheets that may be priced for a similar long runway.Bayer is pouring US$2.2b into specialty pharma manufacturing just as the shares have pulled back over 1 and 3 months. Does that combination still tilt the risk reward in favour of buyers at today’s price?
Most Popular Narrative: 24% Undervalued
The most followed narrative puts Bayer’s fair value at €58.22, compared with the latest close at €44.44. This frames the Ohio investment against a wider rerating story shaped by pharma execution and litigation progress.
Sustained advances in Bayer's pharmaceutical innovation pipeline, evidenced by robust uptake in recently launched drugs and promising late-stage assets (such as asundexian and new indications for existing blockbusters), are positioned to offset patent expirations and generic erosion, supporting both revenue replacement and setting a path for higher margins in later years as these assets scale.
See why 159 investors see Bayer as 24% undervalued.
Result: Fair Value of €58.22 (UNDERVALUED)
Still, Bayer’s narrative can be knocked off course if glyphosate or PCB litigation drags on at higher than expected cost, or if key crop protection products face tighter regulation.
Find out about the key risks to this Bayer narrative.
Next Steps
Mixed signals on Bayer so far. If you want to move fast and still rely on the data, take a closer look at its 4 key rewards.
Looking for more Bayer investment ideas?
If Bayer has sharpened your appetite for opportunity, do not stop here. Cast the net wider now so you are not chasing the next move late.
- Target potential mispricings by scanning a focused set of 178 high quality undervalued stocks that combine solid fundamentals with compressed expectations.
- Strengthen portfolio resilience by reviewing a list of solid balance sheet and fundamentals (206 results) that can help anchor returns when conditions get tougher.
- Hunt for tomorrow's leaders early by running through a 617 high quality undiscovered gems before the market starts paying closer attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com